Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from CHST11 over-expression in A-549 or NCI-H358 cells

ABSTRACT: To examine the CHST11 controls transcriptome in NSCLC cells, we preformed the Affymetrix Human Genome U133 Plus 2.0 Array with empty vector or CHST11 expression vector in A-549 or NCI-H358 cells Then the transcriptome were compared with each other to see the CHST11-regulating gene in NSCLC cells

ORGANISM(S): Homo sapiens

PROVIDER: GSE131952 | GEO | 2022/08/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from CHST11 over-expression in A-549 or NCI-H358 cells

Project description:Expression data from CHST11 over-expression in A-549 or NCI-H358 cells

| PRJNA545431 | ENA

Comparison of gene expression in control and BRG1-knockdown H358 cell lines

Project description:Transcription was assessed in the human H358 NSCLC cell line after knockdown of BRG1, one of the mutually exclusive subunits of the SWI/SNF chromatin remodeling complex, by 2 different shRNAs.

2014-09-23 | GSE58542 | GEO

Expression data from NCI-H1299 and NCI-H1299/CDDP cells

Project description:Non-small cell lung cancer (NSCLC) patients are prone to drug resistance during chemotherapy. Therefore, in order to compare the changes in the gene expression profiles of NSCLC cells before and after drug resistance, we constructed cisplatin-resistant cells (NCI-H1299/CDDP), and compared the gene expression profiles with those of the parental NCI-H1299 cells. We used microarrays to study in detail the global gene expression changes before and after drug resistance in NSCLC cells and identified genes that were up- or down-regulated during this process.

2024-01-14 | GSE252795 | GEO

Comparison of gene expression in control and BRG1-knockdown H358 cell lines

2014-09-23 | E-GEOD-58542 | biostudies-arrayexpress

Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor

Project description:We report RNAseq gene expression data following ARS-1620 treatment and shKRAS expressing cells (NCI-H358). We also compare gene expression changes following treatment with ARS-1620 or trametinib in NCI-H358, LU65 (KRAS-G12C+), and A549 (KRAS-G12S+) cells. Additionally we report a time course (4, 24, 48hr) of ARS-1620 and trametinib treated NCI-H358 cells.

2018-01-24 | GSE103021 | GEO

Expression data from AKR1C1 over-expression in Cal-27 cells or knockdown in HSC-2 cells, respectively

Project description:To exmaine the AKR1C1 controls transcriptome in HNSCC cells, we preformed the Affymetrix Human Genome U133 Plus 2.0 Array with empty vector or AKR1C1 expression vector in Cal-27 cells and shLuc control or shAKR1C1 in HSC-2 cells

2019-12-18 | GSE119444 | GEO

NCI-H1299 cell line transfected with human DENND2D and vector

Project description:Gene expression for NCI-H1299 cell line transfected with human DENND2D and vector (pcDNA3.1/V5-His TOPO TA vector) respectively.

2010-05-04 | GSE16890 | GEO

Epithelial mesenchymal transition using doxycycline-inducible Snail, Zeb1, TGFbeta or Vector in H358 NSCLC cell line

Project description:Epithelial mesenchymal transition using doxycycline-inducible Snail, Zeb1, TGFbeta or Vector in H358 NSCLC cell line

| PRJNA515267 | ENA

Expression data from ectopic PTHLH over-expression in Ca9-22 cells

Project description:To exmaine the PTHLH stimulated genes in Ca9-22 cells, we preformed the Affymetrix Human Genome U133 Plus 2.0 Array with empty vector or PTHLH expression vector. The raw data were normalized by GeneSpring GX software and up-load with raw values.

2017-03-08 | GSE81471 | GEO

microRNA profiling of H358 non-small cell lung cancer cells selected for resistance against erlotinib or wild-type

Project description:Erlotinib is a tyrosine kinase inhibitor (TKI) that is approved as a second-line monotherapy in patients with advanced non-small cell lung cancer (NSCLC). In these patients, erlotinib prolongs survival but its benefit remains modest since overtime, many tumors develop resistance. To analyse the changes in the gene expression profile, that accompany resistance development, we treated the erlotinib sensitive non-small cell lung cancer cell line H358 with increasing concentrations of erlotinib (1-5µM) for several weeks (H358res). In parallel, we kept H358 with the same concentrations of the vehicle DMSO (H358co). After ten weeks of treatment, when the H358res stably grew under 5µM erlotinib, total RNA including microRNA of both cell lines was harvested and analyzed.

2015-09-15 | E-MTAB-3391 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data